Publication: Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?
Issued Date
2011-11-01
Resource Type
ISSN
14681293
14642662
14642662
Other identifier(s)
2-s2.0-80054840297
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
HIV Medicine. Vol.12, No.10 (2011), 610-619
Suggested Citation
H. McManus, Pck Li, D. Nolan, M. Bloch, S. Kiertiburanakul, J. Y. Choi, B. Mulhall, K. Petoumenos, J. Zhou, M. Law, B. J. Brew, E. Wright Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?. HIV Medicine. Vol.12, No.10 (2011), 610-619. doi:10.1111/j.1468-1293.2011.00938.x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/12255
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?
Abstract
Objectives: The aim of the study was to determine whether combination antiretroviral therapy (cART) with high central nervous system penetration-effectiveness (CPE) rank (neurocART) is associated with increased survival benefit compared with non-neurocART. Methods: Prospective data were examined for HIV-positive patients in the Asia Pacific HIV Observational Database who had commenced cART. CPE rank was calculated using the 2010 rankings process. NeurocART status was assigned to regimens with a CPE rank of 8 or more. Survival was analysed using Cox proportional hazards models with covariates updated at changes in cART regimen and with deaths up to 90 days after regimen cessation attributed to that regimen. Sensitivity analyses were conducted to examine the robustness of analysis assumptions. Results: Among 5882 patients, 308 deaths occurred. The hazard ratio (HR) for neurocART use was 0.89 (P=0.35) when data were stratified by cohort and adjusted for age, mode of HIV exposure, hepatitis B virus coinfection, AIDS-defining illness, CD4 count (cells/μL) and regimen count. Sensitivity analyses showed similar nonsignificant results. We also examined a composite endpoint of AIDS-defining illness or death (HR=0.93; P=0.61), baseline regimen as neurocART (HR=0.95; P=0.69), CPE category (P=0.71) and prior neurocART duration (P=0.16). No association between CD4 cell count and neurocART use was observed (P=0.52). Conclusions: Our findings do not show a significant overall survival benefit associated with neurocART compared with cART. The potential benefit associated with neurocART in terms of prevention of neurocognitive impairment did not translate into an improvement in overall survival in this population. These findings were limited by the low incidence of associated mortality. Further studies and more extensive data are needed to address these limitations. © 2011 British HIV Association.